The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Adalimumab (Brand name: Humira)
- Manufactured by
FDA-approved indication: Treatment of Juvenile Idiopathic Arthritis.
Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.
National Library of Medicine Drug Information PortalMedline Plus Health Information